Bacterial infections:
Indications for: ORBACTIV
Susceptible acute bacterial skin and skin structure infections (ABSSSI).
Adult Dosage:
Give by IV infusion over 3hrs. ≥18yrs: 1200mg as a single dose.
Children Dosage:
<18yrs: not established.
ORBACTIV Contraindications:
Use of IV unfractionated heparin sodium for 120hrs (5 days) after oritavancin administration.
ORBACTIV Warnings/Precautions:
History of glycopeptide allergy. Discontinue immediately if acute hypersensitivity reaction occurs. Stop or slow the infusion if infusion-related reactions occur. Evaluate if Clostridioides difficile-associated diarrhea is suspected or confirmed. Monitor for osteomyelitis; use alternative therapy if suspected or diagnosed. Severe hepatic or renal impairment: not studied. Pregnancy. Nursing mothers.
ORBACTIV Classification:
Lipoglycopeptide.
ORBACTIV Interactions:
Increased risk of bleeding with concomitant warfarin; may prolong aPTT for up to 120hrs, PT/INR for up to 12hrs, and ACT for up to 24hrs; monitor for bleeding. Avoid concomitant with drugs that are predominantly metabolized by one of the affected CYP450 enzymes. May increase concentrations of CYP2C9/CYP2C19 substrates. May decrease concentrations of CYP3A4/CYP2D6 substrates. May prolong certain lab coagulation tests; consider non-phospholipid dependent test (eg, Factor Xa assay) or alternative anticoagulant not requiring aPTT monitoring.
Adverse Reactions:
Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea; infusion-related reactions.
Generic Drug Availability:
NO
How Supplied:
Single-dose vials—3
